Bufexamac Chemical Structure

Bufexamac Chemical Structure
Molecular Weight: 223.27

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Bufexamac is available in the following compound libraries:

Product Information

  • Compare COX Inhibitors
    Compare COX Products
  • Research Area

Product Description

Biological Activity

Description Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.
Targets IFN-α [1]
IC50 8.9 μM
In vitro Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Treatment of peripheral blood mononuclear cells with bufexamac inhibits the secretion of IFN-α. [1] Bufexamac is a frequent and relevant contact sensitizer. Bufexamac is a non-steroidal anti-inflammatory drug. [2]
In vivo
Features A specific inhibitor of class IIB histone deacetylases.

Protocol(Only for Reference)

Kinase Assay: [1]

Enzymatic deacetylation assays The enzyme activity of purified recombinant HDAC1, HDAC2, HDAC3-NCoR and HDAC6 (1 μg of protein per well) is measured using the Active Motif HDAC Assay Kit in 96-well format following the manufacturer's instructions. Fluorescence measurements (340 nm excitation/460 nm emission) are recorded with an Analyst HT plate reader in triplicates. Each time series is performed in duplicate. For the determination of enzymatic activity in endogenous HDAC complexes, cell extract samples (375 μL each at 4 mg/mL protein concentration) are prepared from either bufexamac- or vehicle-treated HeLa cultures and are incubated with 15 μg of each antibody for 2 hours at 4 °C. Subsequently, 60 μL Protein G beads equilibrated in lysis buffer containing 0.4% NP40 are added and, following incubation for 1 hour at 4 °C, beads are washed twice with lysis buffer followed by 10 volumes of Assay buffer (HDAC Assay Kit). 10 μL of beads per well is added and deacetylation activity is determined as described above after 150 minutes in the absence or presence of 10 μM trichostatin A. Each point is measured in triplicate. Statistical significance is assessed by unpaired Student's t-test.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Bantscheff M, et al. Nat Biotechnol. 2011, 29(3), 255-265.

[2] Kr?nke B, et al. Contact Dermatitis. 1997, 36(4), 212-215.

Chemical Information

Download Bufexamac SDF
Molecular Weight (MW) 223.27
Formula

C12H17NO3

CAS No. 2438-72-4
Storage 3 years -20℃Powder
6 months-80℃in solvent (DMSO, water, etc.)
Synonyms
Solubility (25°C) * In vitro DMSO 45 mg/mL (201.54 mM)
Water <1 mg/mL (<1 mM)
Ethanol 3 mg/mL (13.43 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(4-butoxyphenyl)-N-hydroxyacetamide

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related COX Products

  • Meclofenamate Sodium

    Meclofenamate Sodium is a dual COX-1/COX-2 inhibitor with IC50 of 40 nM and 50 nM, respectively, used in the treatment of joint, muscular pain, arthritis and dysmenorrhea.

  • FLI-06

    FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.

  • LY2119620

    LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors.

  • Celecoxib

    Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ibuprofen Lysine

    Ibuprofen Lysine is a non-steroidal anti-inflammatory drug.

  • Ibuprofen

    Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

    Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

  • Piroxicam

    Piroxicam is a non-selective COX inhibitor with an IC50 of 6 mM.

  • Diclofenac Sodium

    Diclofenac Sodium is a non-selective COX inhibitor with IC50 of 60 and 220 nM for ovine COX-1 and -2, respectively.

  • Lumiracoxib

    Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4.

Recently Viewed Items

Tags: buy Bufexamac | Bufexamac ic50 | Bufexamac price | Bufexamac cost | Bufexamac solubility dmso | Bufexamac purchase | Bufexamac manufacturer | Bufexamac research buy | Bufexamac order | Bufexamac mouse | Bufexamac chemical structure | Bufexamac mw | Bufexamac molecular weight | Bufexamac datasheet | Bufexamac supplier | Bufexamac in vitro | Bufexamac cell line | Bufexamac concentration | Bufexamac nmr
Contact Us